Identity and Access Management Software Provider BIO-key Reports Q1’24 Revenue of $2.2M and Positive Operating Cash Flow; Hosts Investor Call Tuesday, 10am ET
BIO-key International (Nasdaq: BKYI), a leader in Identity and Access Management solutions, reported Q1'24 revenue of $2.2M, consistent with Q1'23 and a 19.5% increase from Q4'23. Gross profit surged to $1.9M, with a gross margin of 86.3% due to higher software license fees and reduced hardware reserve expenses. Operating expenses were cut by over $0.2M. The company reduced its net loss to $0.5M from $1.7M in Q1'23 and achieved positive operating cash flow of $0.3M. Recent deployments include Fargo, ND, and Bridgetown, Barbados. The company remains focused on revenue growth and profitability, leveraging a strong cybersecurity market and its unique passwordless authentication solutions. An investor call is scheduled for June 18th at 10:00am ET.
- Q1'24 revenue of $2.2M, consistent with Q1'23 and 19.5% higher than Q4'23.
- Gross profit increased to $1.9M (86.3% gross margin) from $0.9M (40% gross margin) in Q1'23.
- Operating expenses reduced by over $0.2M.
- Net loss reduced to $0.5M from $1.7M in Q1'23.
- Positive operating cash flow of $0.3M in Q1'24.
- Deployment of biometric solutions in Fargo, ND, and Bridgetown, Barbados.
- Expansion of biometric technology license with a long-term financial services client.
- Services revenue decreased due to the loss of a large service agreement.
- Decline in recurring and custom services and hardware revenue.
- Higher audit and reporting expenses.
- Net cash position of $690,449, indicating potential liquidity concerns.
Insights
The financial results for Q1'24 indicate a significant improvement for BIO-key in several key metrics. The company reported revenues of
One of the most notable improvements is in the company's gross profit, which more than doubled to
Furthermore, operating cash flow turned positive with a
From an investor’s perspective, these financial metrics signify a company that is making solid progress in stabilizing its revenue and improving profitability. However, the net loss still indicates that the company is not yet profitable, which remains a critical consideration for long-term investment.
BIO-key's offering revolves around its innovative Identity and Access Management (IAM) solutions, including passwordless and tokenless biometric authentication. These technologies are becoming increasingly relevant as organizations move towards more secure and user-friendly authentication methods.
The introduction of Passkey:YOU, a passwordless authentication solution, aligns well with current cybersecurity trends favoring multi-factor authentication and zero-trust security frameworks. This market trend, combined with the growing adoption of cloud infrastructure, provides a compelling growth narrative for BIO-key. Their focus on reducing costs and enhancing high-margin recurring revenues indicates a strategic pivot to more sustainable business models.
The fact that new customers in Fargo, ND and Junction City, KS, as well as a Barbados Credit Union, have adopted BIO-key’s solutions, showcases the growing trust and adoption of their technology in various sectors.
For investors, the technical advancements and adoption of BIO-key's solutions are promising, yet it's important to monitor the company's ability to scale these technologies and convert them into consistent, high-margin revenues.
HOLMDEL, N.J., June 17, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (Nasdaq: BKYI), an innovative provider of workforce and customer Identity and Access Management (IAM) solutions featuring passwordless, phoneless and token-less Identity-Bound Biometric (IBB) authentication, announced results for its first quarter ended March 31, 2024 (Q1’24). Note, BIO-key’s results for the first three quarters of 2023 were restated at year-end and filed with the Company’s 2023 Form 10-K, and as a result Q1’23 comparisons in this release have been restated. BIO-key will host an investor call Tuesday, June 18th at 10:00am ET (details below).
Q1 Financial Highlights
- Q1’24 revenues of
$2.2M were in line with Q1’23 and increased19.5% from Q4’23 revenues of$1.8M - Gross profit increased to
$1.9M (86.3% gross margin) from$0.9M (40% gross margin) in Q1’23, reflecting the impact of a Q1’23$0.5M hardware inventory reserve, as well as higher software license fees in Q1’23 due to higher royalty payments on third-party software solutions. - Operating expenses were reduced over
$0.2M in Q1’24 versus Q1’23, reflecting ongoing cost management initiatives. - BIO-key reported a Q1’24 net loss of
$0.5M compared to a net loss of$1.7M in Q1’23 - Cash generated from operating activities improved to
$0.3M in Q1’24 vs. a$1.9M cash used in Q1’23, principally reflecting the benefit of a$1.5M cash payment in Q1’24 for 2-year extension/expansion of biometric technology license with a long-term financial services customer.
Other Recent Software Deployments:
- Fargo, ND and Junction City, KS Chose PortalGuard with Biometric Authentication
- Bridgetown, Barbados Credit Union Selected PortalGuard with Biometrics for Shared Workstations
Commentary
BIO-key CEO, Mike DePasquale commented, “BIO-key delivered solid progress in Q1’24, achieving positive cash flow from operations in the period, on revenue of
“We remain focused on driving revenue growth and progressing our business to profitability and positive cash flow over the next several quarters. We are encouraged by the traction building within our global Channel Alliance Partner program and with the larger-scale customer dialogues in which we are engaged through our in-house direct sales effort. We believe the cybersecurity landscape continues to provide a compelling backdrop for our company, as we expect it will generate increased demand for secure, zero-trust Identity and Access Management solutions that are the core of our offerings.
“Tailwinds that we expect to support our growth include a growing proportion of enterprises that are moving IT infrastructure to the cloud as well as increasingly stringent regulatory standards as well as cyber insurance underwriting requirements, much of which are now mandating multi-factor authentication or passwordless security solutions that BIO-key is well positioned to provide on a very competitive basis.
“We are also very bullish on the growth potential for passkey authentication this year and going forward. We entered this market with the recent launch of Passkey:YOU – BIO-key’s unique passwordless authentication solution that leverages our strength in biometric security to deliver secure passkeys without the use of phones or hardware tokens.
“We continue to pursue large enterprise opportunities through our direct sales channel, looking to build on recent successes in this area. We are also working to support our global channel partners in developing new customer opportunities to further build our end-user base. Our efforts have forged a growing base of high-margin annually recurring revenues (ARRs) and believe there is substantial potential to grow our ARR base moving forward. At the same time, we will continue to pursue cost reduction opportunities to accelerate our path to profitability and positive cash flow. We are also working to identify potential strategic opportunities to leverage our growing global base of customers to accelerate shareholder value creation. For these and other reasons, we believe BIO-key is well-positioned for the future.”
Financial Results
Q1’24 revenues of
Gross profit grew over
Total operating expenses were reduced by approximately
Reflecting revenue strength and lower operating costs, BIO-key trimmed its net loss by
Balance Sheet
At March 31, 2024, BIO-key had current assets of approximately
| Conference Call Details | |
| Date / Time: | Tuesday, June 18th at 10 a.m. ET |
| Call Dial In #: | 1-877-418-5460 U.S. or 1-412-717-9594 Int’l |
| Live Webcast / Replay: | Webcast & Replay Link – Available for 3 months. |
| Audio Replay: | 1-877-344-7529 U.S. or 1-412-317-0088 Int’l; code 1988012 |
About BIO-key International, Inc. (www.BIO-key.com)
BIO-key is revolutionizing authentication and cybersecurity with biometric-centric, multi-factor identity and access management (IAM) software securing access for over forty million users. BIO-key allows customers to choose the right authentication factors for diverse use cases, including phoneless, tokenless, and passwordless biometric options. Its hosted or on-premise PortalGuard IAM solution provides cost-effective, easy-to-deploy, convenient, and secure access to computers, information, applications, and high-value transactions.
BIO-key Safe Harbor Statement
All statements contained in this press release other than statements of historical facts are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 (the "Act"). The words "estimate," "project," "intends," "expects," "anticipates," "believes" and similar expressions are intended to identify forward-looking statements. Such forward-looking statements are made based on management's beliefs, as well as assumptions made by, and information currently available to, management pursuant to the "safe-harbor" provisions of the Act. These statements are not guarantees of future performance or events and are subject to risks and uncertainties that may cause actual results to differ materially from those included within or implied by such forward-looking statements. These risks and uncertainties include, without limitation, our history of losses and limited revenue; our ability to raise additional capital to satisfy working capital needs; our ability to continue as a going concern; our ability to protect our intellectual property; changes in business conditions; changes in our sales strategy and product development plans; changes in the marketplace; continued services of our executive management team; security breaches; competition in the biometric technology industry; market acceptance of biometric products generally and our products under development; our ability to convert sales opportunities to customer contracts; our ability to expand into Asia, Africa and other foreign markets; our ability to integrate the operations and personnel of Swivel Secure into our business; fluctuations in foreign currency exchange rates; delays in the development of products, the commercial, reputational and regulatory risks to our business that may arise as a consequence the restatement of our financial statements, including any consequences of non-compliance with Securities and Exchange Commission (“SEC”) and Nasdaq periodic reporting requirements; our temporary loss of the use of a Registration Statement on Form S-3 to register securities in the future; any disruption to our business that may occur on a longer-term basis should we be unable to remediate during fiscal year 2024 certain material weaknesses in our internal controls over financial reporting, and statements of assumption underlying any of the foregoing as well as other factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2022 and other filings with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date made. Except as required by law, we undertake no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise.
| Engage with BIO-key | |
| Facebook – Corporate: | https://www.facebook.com/BIOkeyInternational/ |
| LinkedIn – Corporate: | https://www.linkedin.com/company/bio-key-international |
| Twitter – Corporate: | @BIOkeyIntl |
| Twitter – Investors: | @BIO_keyIR |
| StockTwits: | BIO_keyIR |
Investor Contacts
William Jones, David Collins
Catalyst IR
BKYI@catalyst-ir.com or 212-924-9800
| BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited) | ||||||||
| Three Months Ended | ||||||||
| March 31, | ||||||||
| 2024 | 2023 | |||||||
| Revenues | ||||||||
| Services | $ | 213,122 | $ | 532,522 | ||||
| License fees | 1,950,434 | 1,578,556 | ||||||
| Hardware | 17,647 | 72,689 | ||||||
| Total revenues | 2,181,203 | 2,183,767 | ||||||
| Costs and other expenses | ||||||||
| Cost of services | 138,849 | 154,801 | ||||||
| Cost of license fees | 148,221 | 620,881 | ||||||
| Cost of hardware | 12,573 | 44,592 | ||||||
| Cost of hardware - reserve | - | 500,000 | ||||||
| Total costs and other expenses | 299,643 | 1,320,274 | ||||||
| Gross profit | 1,881,560 | 863,493 | ||||||
| Operating Expenses | ||||||||
| Selling, general and administrative | 1,782,973 | 1,931,732 | ||||||
| Research, development and engineering | 607,521 | 690,159 | ||||||
| Total Operating Expenses | 2,390,494 | 2,621,891 | ||||||
| Operating loss | (508,934 | ) | (1,758,398 | ) | ||||
| Other income (expense) | ||||||||
| Interest income | 5 | 4 | ||||||
| Loss on foreign currency transactions | - | (15,000 | ) | |||||
| Change in fair value of convertible note | - | 141,991 | ||||||
| Interest expense | (1,356 | ) | (56,919 | ) | ||||
| Total other income (expense), net | (1,351 | ) | 70,076 | |||||
| Loss before provision for income tax | (510,285 | ) | (1,688,322 | ) | ||||
| Provision for (income tax) tax benefit | - | - | ||||||
| Net loss | $ | (510,285 | ) | $ | (1,688,322 | ) | ||
| Comprehensive loss: | ||||||||
| Net loss | $ | (510,285 | ) | $ | (1,688,322 | ) | ||
| Other comprehensive income (loss) – Foreign currency translation adjustment | (62,275 | ) | 72,146 | |||||
| Comprehensive loss | $ | (572,560 | ) | $ | (1,616,176 | ) | ||
| Basic and Diluted Loss per Common Share | $ | (0.32 | ) | $ | (3.51 | ) | ||
| Weighted Average Common Shares Outstanding: | ||||||||
| Basic and diluted | 1,615,323 | 480,833 | ||||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
| BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||||
| March 31, | December 31, | |||||||
| 2024 | 2023 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Cash and cash equivalents | $ | 690,449 | $ | 511,400 | ||||
| Accounts receivable, net | 701,776 | 1,201,526 | ||||||
| Due from factor | 8,250 | 99,320 | ||||||
| Inventory | 440,194 | 445,740 | ||||||
| Prepaid expenses and other | 427,685 | 364,171 | ||||||
| Total current assets | 2,268,354 | 2,622,157 | ||||||
| Equipment and leasehold improvements, net | 198,238 | 220,177 | ||||||
| Capitalized contract costs, net | 349,145 | 229,806 | ||||||
| Operating lease right-of-use assets | 23,220 | 36,905 | ||||||
| Intangible assets, net | 1,329,985 | 1,407,990 | ||||||
| Total non-current assets | 1,900,588 | 1,894,878 | ||||||
| TOTAL ASSETS | $ | 4,168,942 | $ | 4,517,035 | ||||
| LIABILITIES | ||||||||
| Accounts payable | $ | 1,212,071 | $ | 1,316,014 | ||||
| Accrued liabilities | 1,189,520 | 1,305,848 | ||||||
| Government loan – BBVA Bank, current portion | 135,835 | 138,730 | ||||||
| Deferred revenue, current | 755,405 | 414,968 | ||||||
| Operating lease liabilities, current portion | 23,797 | 37,829 | ||||||
| Total current liabilities | 3,316,628 | 3,213,389 | ||||||
| Deferred revenue, long term | 143,727 | 28,296 | ||||||
| Deferred tax liability | 22,998 | 22,998 | ||||||
| Government loan – BBVA Bank – net of current portion | 149,861 | 188,787 | ||||||
| Total non-current liabilities | 316,586 | 240,081 | ||||||
| TOTAL LIABILITIES | 3,633,214 | 3,453,470 | ||||||
| Commitments and Contingencies | ||||||||
| STOCKHOLDERS’ EQUITY | ||||||||
| Common stock — authorized, 170,000,000 shares; issued and outstanding; 1,814,414 and 1,032,777 of $.0001 par value at March 31, 2024 and December 31, 2023, respectively | 181 | 103 | ||||||
| Additional paid-in capital | 126,092,496 | 126,047,851 | ||||||
| Accumulated other comprehensive loss | (39,454 | ) | 22,821 | |||||
| Accumulated deficit | (125,517,495 | ) | (125,007,210 | ) | ||||
| TOTAL STOCKHOLDERS’ EQUITY | 535,728 | 1,063,565 | ||||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 4,168,942 | $ | 4,517,035 | ||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
| BIO-KEY INTERNATIONAL, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) | ||||||||
| Three Months Ended March 31, | ||||||||
| 2024 | 2023 | |||||||
| CASH FLOW FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (510,285 | ) | $ | (1,688,322 | ) | ||
| Adjustments to reconcile net loss to net cash used for operating activities: | ||||||||
| Depreciation | 23,808 | 13,242 | ||||||
| Amortization of intangible assets | 78,005 | 81,237 | ||||||
| Change in fair value of convertible note | - | (141,991 | ) | |||||
| Amortization of capitalized contract costs | 38,665 | 37,529 | ||||||
| Reserve for inventory | - | 500,000 | ||||||
| Operating leases right-of-use assets | 13,686 | 66,132 | ||||||
| Share and warrant-based compensation for employees and consultants | 47,790 | 59,373 | ||||||
| Stock based directors’ fees | 9,003 | 12,002 | ||||||
| Bad debts | 100,000 | - | ||||||
| Change in assets and liabilities: | ||||||||
| Accounts receivable | 399,749 | (898,881 | ) | |||||
| Due from factor | 91,070 | (33,000 | ) | |||||
| Capitalized contract costs | (158,005 | ) | (8,739 | ) | ||||
| Inventory | 5,545 | 6,554 | ||||||
| Prepaid expenses and other | (63,513 | ) | 2,219 | |||||
| Accounts payable | (116,012 | ) | 88,040 | |||||
| Accrued liabilities | (104,257 | ) | (135,417 | ) | ||||
| Deferred revenue | 455,868 | 178,755 | ||||||
| Operating lease liabilities | (14,033 | ) | (67,544 | ) | ||||
| Net cash provided by (used in) operating activities | 297,084 | (1,928,811 | ) | |||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Capital expenditures | (1,869 | ) | - | |||||
| Net cash used in investing activities | (1,869 | ) | - | |||||
| CASH FLOW FROM FINANCING ACTIVITIES: | ||||||||
| Deferred offering costs | (13,470 | ) | - | |||||
| Proceeds for exercise of warrants | 1,400 | - | ||||||
| Repayment of government loan | (41,821 | ) | (34,289 | ) | ||||
| Net cash used in financing activities | (53,891 | ) | (34,289 | ) | ||||
| Effect of exchange rate changes | (62,275 | ) | 49,913 | |||||
| NET DECREASE IN CASH AND CASH EQUIVALENTS | 179,049 | (1,913,187 | ) | |||||
| CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD | 511,400 | 2,635,522 | ||||||
| CASH AND CASH EQUIVALENTS, END OF PERIOD | $ | 690,449 | $ | 722,335 | ||||
All BIO-key shares issued and outstanding for all periods reflect BIO-key’s 1-for-18 reverse stock split, which was effective December 21, 2023.
FAQ
What were BIO-key's Q1'24 revenues?
What is BIO-key's stock symbol?
How did BIO-key's gross profit change in Q1'24?
When is BIO-key's investor call?
What recent deployments were announced by BIO-key?
What is the net loss reported by BIO-key for Q1'24?
What impacted BIO-key's Q1'24 operating cash flow?
